Interaction Checker

Rimegepant interactions

Rimegepant (Nurtec) has 75 documented interactions across the FDA labels and fact sheets we index: 74 major, 1 moderate, 0 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (74)

  • AbrocitinibJAK inhibitorMajor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)

  • AmiodaroneantiarrhythmicMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • AprepitantCYP3A4 inhibitorMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • ArmodafinilCNS stimulantMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • AtazanavirantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • BosentanCYP3A4 inducerMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • CarbamazepineanticonvulsantMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • CenobamateanticonvulsantMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • CimetidineH2 blockerMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Clarithromycinmacrolide antibioticMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • ClobazambenzodiazepineMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • CyclosporineimmunosuppressantMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • DarunavirantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Darunavir and cobicistatantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Deferasiroxiron supplementMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • DexamethasonecorticosteroidMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Diltiazemcalcium channel blockerMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • DronedaroneantiarrhythmicMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • EfavirenzantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Efavirenz, lamivudine, and tenofovirantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Elvitegravir, cobicistat, emtricitabine, and tenofovirantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Erythromycinmacrolide antibioticMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • EslicarbazepineanticonvulsantMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • EtravirineantiretroviralMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • EverolimusimmunosuppressantMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • FlibanserinCNS depressantMajor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)

  • Fluconazoleazole antifungalMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • FosamprenavirantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • FosaprepitantCYP3A4 inhibitorMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • FosphenytoinanticonvulsantMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • GriseofulvinantifungalMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • ImatinibCYP3A4 inhibitorMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • IsoniazidantibioticMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Itraconazoleazole antifungalMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • IvacaftorCYP3A4 inhibitorMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Ketoconazoleazole antifungalMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • LapatinibP-glycoprotein inhibitorMajor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)

  • Ledipasvir and sofosbuvirantiviralMajor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)

  • LenacapavirantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Lopinavir and ritonavirantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • LorlatinibCYP3A4 inducerMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • MifepristoneCYP3A4 inhibitorMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Mirabegronbeta-adrenergic agonistMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • MitapivatCYP3A4 inducerMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • MitotaneCYP3A4 inducerMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • ModafinilCNS stimulantMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Nafcillinpenicillin antibioticMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • NefazodoneantidepressantMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • NevirapineantiretroviralMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • NilotinibQT-prolonging drugMajor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)

  • Nirmatrelvir and ritonavirantiviralMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • OxcarbazepineanticonvulsantMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • PalbociclibCYP3A4 inhibitorMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • PerampanelanticonvulsantMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • PhenobarbitalbarbiturateMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Phentermine and topiramateCNS stimulantMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • PhenytoinanticonvulsantMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Posaconazoleazole antifungalMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • PrimidoneanticonvulsantMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • PropafenoneantiarrhythmicMajor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)

  • QuinidineantiarrhythmicMajor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)

  • RanolazineQT-prolonging drugMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • RifabutinantibioticMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • RifampinantibioticMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • RifapentineantibioticMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • RitonavirantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Sofosbuvir and velpatasvirantiviralMajor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)

  • Suvorexantsedative-hypnoticMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • SuzetrigineCYP3A4 inducerMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Ticagrelorantiplatelet agentMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • TopiramateanticonvulsantMajor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Verapamilcalcium channel blockerMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • Voriconazoleazole antifungalMajor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)

  • ZonisamideanticonvulsantMajor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)

Moderate interactions (1)

  • Dextromethorphan and quinidineserotonergic drugModerate

    P-gp Inhibitors Concomitant administration of NURTEC ODT with potent inhibitors of P-gp (e.g., amiodarone, cyclosporine, lapatinib, quinidine, ranolazine) may result in increased exposure of rimegepant. (Rimegepant label, Drug interactions)

Check Rimegepant against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.